Skip to main content
DaehanPharmaceutical logo

DaehanPharmaceutical — Investor Relations & Filings

Ticker · 023910 ISIN · KR7023910003 KO Manufacturing
Open in API
Filings indexed 297 across all filing types
Latest filing 2020-01-16 Director's Dealing
Country KR South Korea
Listing KO 023910

About DaehanPharmaceutical

https://www.dhnp.co.kr/

Daehan Nupharm is a pharmaceutical company engaged in the research, development, and manufacturing of a diverse portfolio of healthcare products. The company's business is structured around four core areas: human pharmaceuticals, offering a range of therapeutic treatments; animal health products for both companion and livestock animals; advanced bio-pharmaceuticals, with a focus on next-generation technologies like cell therapy; and health functional foods. Established initially in the animal health sector, the company leverages its dedicated Central and Bio Research Institutes to drive innovation and develop solutions for global markets. The R&D efforts concentrate on strengthening technological capabilities and advancing new treatment modalities.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. This type of filing is a mandatory disclosure by company insiders (directors/executives) regarding their personal share transactions (insider trading). According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2020-01-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is used to disclose personal share transactions by company directors and executives, which corresponds to the 'Director's Dealing' category.
2020-01-03 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서). It details the share transactions (disposals) made by an executive (Oh Chang-min) of Daehan Pharmaceutical Co., Ltd. This type of filing is a standard regulatory requirement for insider trading disclosures, which falls under the 'Director's Dealing' category.
2020-01-03 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required when an entity's shareholding in a listed company crosses a specific threshold (typically 5%). This document details the shareholding changes of Mirae Asset Global Investments in Daehan Pharmaceutical. It is a standard regulatory disclosure form in South Korea, not an announcement of a report, but the report itself.
2020-01-02 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. This type of filing is specifically used to report insider transactions (share purchases/sales) by company directors or major shareholders. Based on the provided categories, this aligns with 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2019-12-13 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement regarding the closure of the shareholder register for the purpose of determining shareholders eligible to vote at the upcoming Annual General Meeting. It does not contain the full report or proxy materials, but rather serves as a formal notice of a corporate action related to shareholder rights and meeting preparation. Given it is a standard regulatory notification that does not fit into specific categories like dividend announcements or share buybacks, it is classified as a general regulatory filing.
2019-12-13 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.